Literature DB >> 2108458

Estimating HIV levels and trends among patients of tuberculosis clinics.

E McCray1, I M Onorato, B I Miller, T J Dondero, A B Bloch.   

Abstract

Symptomatic tuberculosis (TB) can occur as an opportunistic disease in immunosuppressed persons who are infected with human immunodeficiency virus (HIV) and who have been previously infected with Mycobacterium tuberculosis. Increases in TB cases have occurred in areas which have reported large numbers of cases of the acquired immunodeficiency syndrome (AIDS), and a high proportion of these TB cases have been HIV seropositive. Therefore, increasing numbers of HIV-infected persons may be found in TB clinics and hospitals. HIV serologic surveys in TB clinics and hospitals providing clinical services to TB patients are needed to assess the local prevalence of HIV infection in TB patients and the consequent need for public health intervention to prevent further spread of HIV and TB infection. The Centers for Disease Control (CDC), in collaboration with State and local health departments, has initiated HIV surveillance of patients with confirmed and suspected TB in TB clinics and hospitals in the United States. Blinded (serologic test results not linked to identifiable persons) HIV seroprevalence surveys are conducted in sentinel TB clinics and hospitals that provide TB clinical services each year to obtain estimates of the level of HIV infection in TB patients and to follow trends in infection over time. Nonblinded (voluntary) surveys will also be conducted to evaluate behaviors that have placed TB patients at risk for or protected them against HIV infection. Data from these surveys will be used to target education and prevention and control programs for TB and HIV infection and to monitor changes in behavior in response to such programs.

Entities:  

Mesh:

Year:  1990        PMID: 2108458      PMCID: PMC1580065     

Source DB:  PubMed          Journal:  Public Health Rep        ISSN: 0033-3549            Impact factor:   2.792


  7 in total

1.  Increasing incidence of tuberculosis in a prison inmate population. Association with HIV infection.

Authors:  M M Braun; B I Truman; B Maguire; G T DiFerdinando; G Wormser; R Broaddus; D L Morse
Journal:  JAMA       Date:  1989-01-20       Impact factor: 56.272

2.  A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection.

Authors:  P A Selwyn; D Hartel; V A Lewis; E E Schoenbaum; S H Vermund; R S Klein; A T Walker; G H Friedland
Journal:  N Engl J Med       Date:  1989-03-02       Impact factor: 91.245

3.  Failure of "optimal" four-drug short-course tuberculosis chemotherapy in a compliant patient with human immunodeficiency virus.

Authors:  G Sunderam; B T Mangura; J M Lombardo; L B Reichman
Journal:  Am Rev Respir Dis       Date:  1987-12

4.  Tuberculosis as a manifestation of the acquired immunodeficiency syndrome (AIDS).

Authors:  G Sunderam; R J McDonald; T Maniatis; J Oleske; R Kapila; L B Reichman
Journal:  JAMA       Date:  1986-07-18       Impact factor: 56.272

5.  CDC's Model Performance Evaluation Program: assessment of the quality of laboratory performance for HIV-1 antibody testing.

Authors:  W O Schalla; T L Hearn; R N Taylor; E Eavenson; R O Valdiserri; J D Essien
Journal:  Public Health Rep       Date:  1990 Mar-Apr       Impact factor: 2.792

6.  Tuberculosis in patients with the acquired immunodeficiency syndrome. Clinical features, response to therapy, and survival.

Authors:  R E Chaisson; G F Schecter; C P Theuer; G W Rutherford; D F Echenberg; P C Hopewell
Journal:  Am Rev Respir Dis       Date:  1987-09

7.  Human T-cell lymphotropic virus-III (HTLV-III) seropositivity and related disease among 71 consecutive patients in whom tuberculosis was diagnosed. A prospective study.

Authors:  A E Pitchenik; J Burr; M Suarez; D Fertel; G Gonzalez; C Moas
Journal:  Am Rev Respir Dis       Date:  1987-04
  7 in total
  5 in total

1.  HIV seroprevalence surveys of childbearing women--objectives, methods, and uses of the data.

Authors:  M Pappaioanou; J R George; W H Hannon; M Gwinn; T J Dondero; G F Grady; R Hoff; A D Willoughby; A Wright; A C Novello
Journal:  Public Health Rep       Date:  1990 Mar-Apr       Impact factor: 2.792

2.  Using seroprevalence data in managing public health programs.

Authors:  I M Onorato; T S Jones; W R Forrester
Journal:  Public Health Rep       Date:  1990 Mar-Apr       Impact factor: 2.792

3.  HIV surveillance testing: taking advantage of the disadvantaged.

Authors:  S H Isaacman
Journal:  Am J Public Health       Date:  1993-04       Impact factor: 9.308

4.  The family of HIV seroprevalence surveys: objectives, methods, and uses of sentinel surveillance for HIV in the United States.

Authors:  M Pappaioanou; T J Dondero; L R Petersen; I M Onorato; C D Sanchez; J W Curran
Journal:  Public Health Rep       Date:  1990 Mar-Apr       Impact factor: 2.792

5.  Trends in tuberculosis/human immunodeficiency virus comorbidity, United States, 1993-2004.

Authors:  Rachel Albalak; Richard J O'Brien; J Steve Kammerer; Sean M O'Brien; Suzanne M Marks; Kenneth G Castro; Marisa Moore
Journal:  Arch Intern Med       Date:  2007-12-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.